Over the last 12 months, we have seen many combination therapies enter Phase I and II trials with both successes and challenges, particularly in solid tumors. The FDA...

It's a chance for senior executives to address shared challenges around innovative product development, build meaningful partnerships, and sharpen their R and D and commercial...